Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: A health economic model based on the PREDICTIVE study

Value in Health

Volumn 15, Issue 1 SUPPL., 2012, Pages

  Yang, Li ^a   Christensen, Torsten ^b   Sun, Fengyu ^c   Chang, Jinghua ^c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b NOVO NORDISK A S   (Denmark)

^c SIBS Novo Nordisk Translational Research Centre for PreDiabetes   (China)

Author keywords

Chinese setting; cost effectiveness; cost utility; insulin detemir

Indexed keywords

INSULIN DETEMIR; INSULIN GLARGINE;

CEREBROVASCULAR DISEASE; CHINESE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; LIFE EXPECTANCY; MEDICAL INFORMATION; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; ULCER;

EID: 84862960902     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.11.018     Document Type: Conference Paper

References (24)

1. W.Y. Yang, J.M. Lu, J.P. Weng Prevalence of diabetes among men and women in China New Engl J Med 362 2010 1090 1101
2. S.L. Hu, G. Liu, Z.R. Xu Current status of epidemic and economic burden of diabetes mellitus in China Chin Health Econ 8 2008 5 8
3. International Diabetes Federation Diabetes Atlas (3rd ed.)[R] http://www.diabetesatlas.org/map?id=13 2007 [Accessed May 22, 2011]
4. H.D. Xiang The epidemiological state and preventive strategy of diabetes or chronic complications in China Bull Med Res 6 2005 6 8
5. X.B. Chen, L. Tang, H.Y. Chen Assessing the impact of complications on the costs of type 2 diabetes in urban China Chin J Diabetes 11 2003 238 291
6. I.M. Stratton, A.I. Adler, H.A.W. Neil Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412 (Pubitemid 30609442)
7. C.Y. Pan Control situation of diabetesdifference between guideline and practice (the outcome of diabetes control in 1998, 2001, 2003) Section Endocrinol Foreign Med Sci 3 2005 174 178
8. W.J. Valentine, G. Goodall, M. Aagren Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Korea: a modelling study of long-term clinical and cost outcomes Adv Ther 25 2008 567 584
9. W.J. Valentine, K.M. Erny-Albrecht, J.A. Ray Therapy conversion to Insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States Adv Ther 24 2007 273 290 (Pubitemid 46988370)
10. A.J. Palmer, W.J. Valentine, J.A. Ray An economic assessment of analogue basalbolus insulin versus human basalbolus insulin in subjects with type 1 diabetes in the UK Curr Res Med Opin 23 2007 895 901 (Pubitemid 46631492)
11. S.L. Tunis, M.E. Minshall, C. Conner Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis Curr Res Med Opin 25 2009 1273 1284
12. M.H. Gschwend, M. Aagren, W.J. Valentine Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries J Med Econ 12 2009 114 123
13. A.J. Palmer, S. Roze, W.J. Valentine The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making Curr Med Res Opin 20 Suppl. 1 2004 S5 S26
14. A.J. Palmer, S. Roze, W.J. Valentine Validation of the CORE diabetes model against epidemiological and clinical studies Curr Med Res Opin 20 Suppl. 1 2004 S27 S40
15. M.V. Srishyla Observational study to evaluate the safety of Levemir® in diabetes http://clinicaltrials.gov/ct2/show/NCT00706017?term= PREDICTIVE&rank=3 [Accessed May 22, 2011]
16. W.P. Jia, C. Pang, L. Chen Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities Diabetologia 50 2007 286 292
17. C. Koenen Observational study of safety and effectiveness of NovoMix® 30 for the treatment of diabetes (IMPROVE™) http://clinicaltrials.gov/ ct2/show/NCT00659282?term=novomix+30+therapy&rank=15 [Accessed May 22, 2011]
18. G.H. Yang, J.M. Ma, N. Liu Smoking and passive smoking in Chinese, 2002 Chin J Epidemiol 2 2005 77 83
19. China Health Care Association The investigation report over smoking and drinking including Chinese twenty-five provinces in 2007 http://www1.chc.org.cn/ news/detail.php?id=51296 [Accessed May 22, 2011]
20. S.K. Sharma, S.R. Joshi, A. Kumar Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study J Assoc Phys India 56 2008 859 863
21. J.L. Palmer, M. Gibbs, H.W. Scheijbeler Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China Adv Ther 25 2008 752 774
22. National Bureau of Statistics of China Statistical Communiqu of the People's Republic of China on the 2008 National Economic and Social Development http://www.stats.gov.cn/tjgb/ [Accessed May 22, 2011]
23. C.J. Currie, C.L. Morgan, C.D. Poole Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes Curr Med Res Opin 22 2006 1523 1534 (Pubitemid 44297431)
24. World Health Organization Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis 2003 World Health Organization Geneva